Two headlines from AstraZeneca landed within weeks of each other this summer: a licensing deal for Zegfrovy and a tumour-agnostic EU approval for Enhertu.

Pharmaceutical giants are strategically evolving, investing in innovation, talent, and infrastructure to drive global healthcare forward.